CLSD:NSD-Clearside Biomedical, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.41

Change

-0.04 (-1.16)%

Market Cap

USD 0.19B

Volume

0.32M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia. Address: 900 North Point Parkway, Alpharetta, GA, United States, 30005

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.59 (-6.73%)

USD62.28B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.68 (+0.80%)

USD54.69B 20.45 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.19 (-1.77%)

USD49.61B 15.17 11.55
ALXN Alexion Pharmaceuticals, Inc

-1.60 (-1.05%)

USD33.27B 55.63 33.22
RPRX Royalty Pharma plc

-1.08 (-2.25%)

USD29.16B 22.60 14.17
BGNE BeiGene, Ltd

-12.93 (-4.05%)

USD29.03B N/A N/A
SGEN Seagen Inc

+1.16 (+0.76%)

USD27.64B 45.27 37.70
BNTX BioNTech SE

-5.23 (-4.75%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.29 (-3.67%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLSD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.45% 64% D 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.45% 64% D 73% C
Trailing 12 Months  
Capital Gain 40.33% 54% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.33% 54% F 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.52% 38% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.52% 38% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 68.56% 39% F 19% F
Risk Adjusted Return -0.75% 38% F 32% F
Market Capitalization 0.19B 30% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 23.29 10% F 8% F
Price / Cash Flow Ratio -7.20 42% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -158.74% 16% F 7% F
Return on Invested Capital -121.45% 19% F 7% F
Return on Assets -39.97% 27% F 8% F
Debt to Equity Ratio 34.23% 34% F 53% F
Technical Ratios  
Short Ratio 0.63 74% C 72% C-
Short Percent 1.11% 91% A- 78% C+
Beta 1.42 50% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector